General
Preferred name
EDIVOXETINE
Synonyms
Edivoxetine HCl ()
EDIVOXETINE HYDROCHLORIDE ()
LY-2216684 HYDROCHLORIDE ()
LY2216684 ()
LY-2216684 ()
LY2216684 HCL ()
P&D ID
PD008914
CAS
1194508-25-2
Tags
available
drug candidate
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
This active molecular is a selective norepinephrine reuptake inhibitor that developed for ADHD (attention-deficit hyperactivity disorder) and as an antidepressant agent originated by Eli Lilly. In Jan 2014, Eli Lilly completed a phase III extension trial in adjunctive treatment of major depressive disorder in Japan. In Jul 2015, Eli Lilly terminates phase II/III trial in Attention deficit hyperactivity disorder.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
4
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugBank
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
339.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
1
cLogP
1.52
TPSA
59.95
Fraction CSP3
0.67
Chiral centers
2.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Solubility
Soluble in DMSO
Source data
